WHAT IS CLAIMED IS:

1. An isolated polypeptide comprising:
a) the amino acid sequence of SEQ ID NO: 8;
b) the amino acid sequence of SEQ ID NO: 6, or
c) the amino acid sequence of SEQ ID NO: 2.

2. An antigenic polypeptide comprising:
a) an immunogenic amino acid sequence exhibiting identity overall length of at least 12 amino acids to SEQ ID NO: 8;
b) an immunogenic amino acid sequence exhibiting identity over a length of at least 12 amino acids to SEQ ID NO: 6; or
c) an immunogenic amino acid sequence exhibiting identity over a length of at least 12 amino acids to SEQ ID NO: 2.

3. An antigenic polypeptide of:
a) Claim 2a, further comprising:
i) a second length of identity of 12 amino acids;
ii) a detection or purification tag;
iii) a sequence of another chemokine receptor; or
iv) a carbohydrate;
b) Claim 2b, further comprising:
i) a second length of identity of 12 amino acids;
ii) a detection or purification tag;
iii) a sequence of another chemokine receptor; or
iv) a carbohydrate; or
c) Claim 2c, further comprising:
i) a second length of identity of 12 amino acids;
ii) a detection or purification tag;
iii) a sequence of another chemokine; or

iv) a carbohydrate.

4. The polypeptide of Claim 1, which;

a) has a molecular weight of at least 3 kD with natural glycosylation;

b) is a synthetic polypeptide;

c) is attached to a solid substrate;

d) is conjugated to another chemical moiety;

e) is a 5-fold or less substitution from natural sequence; or

f) is a deletion or insertion variant from a natural sequence.

5. A composition comprising:

a) a sterile polypeptide of Claim 1a,

b) a sterile polypeptide of Claim 1b; or

c) a sterile polypeptide of Claim 1c.

6. A kit comprising a polypeptide of Claim 1, and:

a) a compartment comprising said polypeptide; and/or

b) instructions for use or disposal of reagents in said kit.

7. A method of using said polypeptide of Claim 1 to:

a) produce an antiserum, comprising immunizing an animal with said polypeptide, and isolating said antiserum; or

b) produce an antibody:antigen complex, comprising contacting said polypeptide with a specific antibody, thereby producing said complex.

8. A binding compound comprising an antigen binding portion from an antibody, which specifically binds to a polypeptide of Claim 1, wherein:

a) said binding compound is an Fv, Fab, or Fab2 fragment;

b) said binding compound is conjugated to another chemical moiety; or

c) said antibody:

i) is raised against a peptide sequence of a mature polypeptide of Figure 1 or Figures 3A-3C;

ii) is raised against a peptide sequence of a mature rodent polypeptide of Figure 5;

iii) is immunoselected;

iv) is a polyclonal antibody;

v) binds to a denatured rodent CXC N4, rodent DNAXCCR10, or primate BLRx;

vi) exhibits a Kd to antigen of at least 30 μM;

vii) is attached to a solid substrate, including a bead or plastic membrane;

viii) is in a sterile composition; or

ix) is detectably labeled, including a radioactive or fluorescent label.

9. A kit comprising said binding compound of Claim 8, and:

a) a compartment comprising said binding compound; and/or

b) instructions for use or disposal of reagents in said kit.

10. A composition comprising:

a) a sterile binding compound of Claim 8; or

b) said binding compound of Claim 8 and a carrier, wherein said carrier is:

i) an aqueous compound, including water, saline, and/or buffer; and/or

ii) formulated for oral, rectal, nasal, topical, or parenteral administration.

11. An isolated or recombinant nucleic acid encoding a polypeptide of Claim 1, wherein said nucleic acid:

a) encodes an antigenic peptide sequence of Figure 1 or Figures 3A-3C;

b) encodes an antigenic rodent peptide sequence of Figure 5;

c) encodes a plurality of antigenic peptide sequences of Figure or Figures 3A-3C;

d) encodes a plurality of antigenic peptide sequences of Figures 2A-2B;

e) exhibits identity of at least 27 nucleotides of SEQ ID NO: 7, 5, or 1;

f) is an expression vector;

g) further comprises an origin of replication;

h) is from a natural source;

i) comprises a detectable label;

j) comprises synthetic nucleotide sequence;

k) is less than 6 kb, preferably less than 3 kb;

l) is from a mammal, including a rodent;

m) comprises a natural full length coding sequence;

n) is a hybridization probe for a gene encoding said protein; or

o) is a PCR primer, PCR product, or mutagenesis primer.

12. A cell or tissue comprising a recombinant nucleic acid of Claim 11.

13. The cell of Claim 12, wherein said cell is:

a) a prokaryotic cell;

b) a eukaryotic cell;

c) a bacterial cell;

d) a yeast cell;

e) an insect cell;

f) a mammalian cell;

g) a mouse cell;

h) a primate cell; or

i) a human cell.

14. A kit comprising said nucleic acid of Claim 11, and:

a) a compartment comprising said nucleic acid;

b) a compartment further comprising a polypeptide of SEQ ID NO: 8, 6, or 2; and/or

c) instructions for use or disposal of reagents in said kit.

15. A nucleic acid which:

a) hybridizes under wash conditions of 45° C and less than 700 mM salt to SEQ ID NO: 1;

b) hybridizes under wash conditions of 45° C and less than 700 mM salt to SEQ ID NO: 5;

c) hybridizes under wash conditions of 45° C and less than 700 mM salt to SEQ ID NO: 7;

d) exhibits identity over a stretch of 30 nucleotides to SEQ ID NO: 7;

e) exhibits identity over at least 30 nucleotides to SEQ ID NO: 5; or

f) exhibits identity over at least 30 nucleotides to SEQ ID NO 1.

16. The nucleic acid of Claim 15, wherein:

a) said wash conditions are at 55° C and/or 500 mM salt; or

b) said identity is over at least 55 nucleotides.

17. The nucleic acid of Claim 16, wherein:

a) said wash conditions are at 65° C and/or 150 mM salt; or

b) said identity is over at least 75 nucleotides.

18. A kit comprising said nucleic acid of Claim 15, and:

a) a compartment comprising said nucleic acid;

b) a compartment further comprising a polypeptide of SEQ ID NO: 8, 6, or 2; and/or

c) instructions for use or disposal of reagents in said kit.

19. A method of using said nucleic acid of Claim 15:

a) to produce a duplex nucleic acid, comprising contacting one strand of the nucleic acid to the complementary strand, thereby producing said duplex; or

b) to produce a polypeptide, comprising expressing said nucleic acid in a host cell, thereby producing said polypeptide.

20. A method of screening for a compound which binds to a polypeptide of Claim 1 having SEQ ID NO: 8, comprising contacting said compound to said polypeptide, and detecting binding.

21. An isolated polypeptide, comprising the amino acid sequence of SEQ ID NO:8, or a polypeptide having at least about 80% sequence homology thereto.

22. An isolated polynucleotide encoding the polypeptide of claim 21.

23. The polynucleotide of claim 22, wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO:7, or a polynucleotide having at least about 80% sequence homology thereto.

24. A recombinant vector comprising

(a) a polynucleotide according to claim 22; and

(b) control elements that are operably linked to said polynucleotide whereby a coding sequence within said polynucleotide can be transcribed and translated in a host cell, and at least one of said control elements is heterologous to said coding sequence.

25. A host cell transformed with the recombinant vector of claim 24.

26. A method of producing a recombinant polypeptide comprising:

(a) providing a population of host cells according to claim 25; and

(b) culturing said population of cells under conditions whereby a polypeptide encoded by the coding sequence present in said recombinant vector is expressed.

27. A method of expressing a recombinant polypeptide comprising:

(a) transforming a host cell with the recombinant vector of claim 22; and

(b) causing expression of a polypeptide encoded by the coding sequence present in said recombinant vector.

28. The method of claim 27, wherein the host cell is transformed *in vivo*.

29. The method of claim 28, wherein the host cell is in the region of a wound.

30. A method of treating a wound comprising:

(a) transforming a host cell *in vivo* with the polynucleotide of claim 22, wherein the host cell is in the region of a wound; and

(b) causing expression of a polypeptide encoded by the coding sequence present in said recombinant vector.

31. A method of treating a wound comprising modulating the *in vivo* expression of an endogenous polynucleotide in the region of the wound, wherein the polynucleotide encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:8.

32. The method of claim 31, wherein expression is up-regulated.

33. An antibody reactive with the polypeptide of claim 21.

34. The antibody of claim 33, wherein the antibody is a polyclonal antibody.

35. The antibody of claim 33, wherein the antibody is a monoclonal antibody.

36. A method of treating a wound comprising administering the antibody of claim 33 to a subject in need thereof.